This site is intended for Healthcare professionals only.

Strides JV gets USFDA nod for Albendazole tablets

Strides JV gets USFDA nod for Albendazole tablets

New Delhi: Drug firm Strides Pharma Science recently said its joint venture (JV) firm has received approval from the US health regulator for Albendazole tablets, used in the treatment of certain infections caused by the tapeworm.

Strides Vivimed Pte Ltd, Singapore, a 50:50 joint venture with Vivimed Labs, has received approval from the United States Food & Drug Administration (US FDA) for Albendazole tablets in the strength of 200 mg, Strides Pharma Science said in a BSE filing.

This is the second generic approval by US FDA for Albendazole tablets, the company added.

Strides Pharma Science said the approved product is a generic version of Amneal Pharmaceuticals Inc’s Albenza tablets.

Quoting IQVIA MAT data, Strides Pharma Science said the US market for Albendazole tablets USP 200 mg is approximately USD 100 million.

Strides Pharma Science Limited(Strides), incorporated in 1990, is a global pharmaceutical Company, headquartered in Bangalore, India. The Company is listed on the Bombay Stock Exchange and National Stock Exchange of India Limited.

Read Also: Strides Pharma board approves USD 15 million investment in Stelis Biopharma

The following two tabs change content below.
MD Team

MD Team

At Medical Dialogues, we are a team of young professionals strongly advocating of the transparency in the medical sector through the free flow of medical information, health and medical news. MD Team covers a variety of news related to the healthcare, pharma and medical device industry in India. Our team can be contacted at Contact no. 011-43720751

Source: PTI
0 comment(s) on Strides JV gets USFDA nod for Albendazole tablets

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted